Replimune's BLA resubmission of RP1 plus nivolumab for melanoma faces an FDA decision by April 10, 2026. REPL's confirmatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results